Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Evaluation of Safety and Efficacy of Rexin-G for Recurrent or Metastatic Pancreatic Cancer

NCT00504998 is registered in ClinicalTrials.gov with Epeius Biotechnologies as lead sponsor.

NCT NCT00504998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00504998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Evaluation of Safety and Efficacy of Rexin-G for Recurrent or Metastatic Pancreatic Cancer
Lead sponsor
Epeius Biotechnologies
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2007
Completion date
June 30, 2011
Enrollment
20 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer